Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
July 27, 2022 08:00 ET
|
Medicenna Therapeutics Corp.
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s low and mid-stage dose escalation cohorts ...
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
June 22, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose escalation cohorts of the ABILITY Phase 1/2...
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent
June 09, 2022 07:30 ET
|
Medicenna Therapeutics Corp.
Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered SuperkinesDelivery of selected Bcl-2 family of proteins can prevent cell death,...
Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022
June 07, 2022 07:30 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting
May 11, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) -- MDNA11 selectively increased a...
Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study
May 02, 2022 08:00 ET
|
Medicenna Therapeutics Corp.
-- Levels of Ki67+ expression by CD8+ T cells and NK cells increased by 17-fold and 10-fold, respectively, in the third cohort (30 µg/kg dose) when compared to baseline -- NK cell / Treg and CD8+T...
Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
April 27, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
April 08, 2022 09:15 ET
|
Medicenna Therapeutics Corp.
-- Anti-PD1-IL-2 BiSKIT (Bi-functional SuperKines for ImmunoTherapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents their exhaustion through PD-1 inhibition --...
Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting
April 08, 2022 09:10 ET
|
Medicenna Therapeutics Corp.
-- Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor -- Fc-MDNA413 inhibits in vivo tumor...
Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 10, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company,...